Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1390, 2003-01, pp. : 19-19
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
PEG IFN- -2a/ribavirin superior to IFN- -2a/ribavirin in HCV + HIV
Inpharma, Vol. 1, Iss. 1449, 2004-01 ,pp. :
Access to resources
Recommend
IFN- -2b + ribavirin preferred initial treatment for hep C
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 274, 2000-01 ,pp. :
IFN- -2b + ribavirin preferred initial treatment for hep C
Inpharma, Vol. 1, Iss. 1249, 2000-01 ,pp. :
Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. :
PEG IFN- -2b + ribavirin superior for HCV + HIV infection
Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. :